Caring Brands, Inc. 8-K

What Happened Caring Brands, Inc. (CABR) filed a Form 8-K on January 5, 2026 disclosing that on December 31, 2025 it entered an exclusive, worldwide license agreement with Itonis Pharmaceuticals to manufacture, market and sell Itonis’s homeopathic product Emesyl. The Company must use commercially reasonable efforts to bring the Product to market, and a press release announcing the deal was filed as Exhibit 99.1.

Key Details

• License date: December 31, 2025; 8-K filed January 5, 2026.
• Royalty: Caring Brands will pay Itonis 8% of Net Sales, payable within 30 days after the end of each calendar quarter, with a quarterly written sales report.
• Manufacturing & data: Company will manufacture the Product at its cost (or may arrange for Itonis to supply by mutual consent); Itonis is expected to provide a technical summary (formulation, nasal spray tech, sourcing, stability, historical sales/cost/regulatory data) within 60 days of the agreement.
• Equity milestone and termination: For each $200,000 in Product sales reached, Caring Brands would be entitled to receive 7% of Itonis’s equity (subject to agreement terms). Exclusivity ends if Product sales are $25,000 or less for four consecutive quarters after the first full calendar quarter post-launch; the agreement is also terminable for uncured material breach.

Why It Matters This agreement gives Caring Brands exclusive global rights to a branded product (Emesyl), creating a new potential revenue stream that would incur an 8% royalty and manufacturing costs. The technical package from Itonis is intended to support a product launch, but exclusivity can lapse if sales are low. Investors should note both the upside (new product sales, possible equity interest in Itonis tied to sales milestones) and the costs/risks (royalty expenses, manufacturing outlays, and termination conditions) disclosed in the 8-K.